Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 14.3 USD 0.7% Market Closed
Market Cap: 989m USD
Have any thoughts about
Zymeworks Inc?
Write Note

Zymeworks Inc
Other Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zymeworks Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Zymeworks Inc
NASDAQ:ZYME
Other Items
$48.1m
CAGR 3-Years
-38%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Items
-$18.9B
CAGR 3-Years
-171%
CAGR 5-Years
N/A
CAGR 10-Years
-21%
Gilead Sciences Inc
NASDAQ:GILD
Other Items
-$3.7B
CAGR 3-Years
31%
CAGR 5-Years
4%
CAGR 10-Years
-18%
Amgen Inc
NASDAQ:AMGN
Other Items
-$26.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Items
-$3.3B
CAGR 3-Years
N/A
CAGR 5-Years
-61%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Items
-$2B
CAGR 3-Years
14%
CAGR 5-Years
-3%
CAGR 10-Years
-21%
No Stocks Found

Zymeworks Inc
Glance View

Market Cap
1B USD
Industry
Biotechnology

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

ZYME Intrinsic Value
18.33 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Zymeworks Inc's Other Items?
Other Items
48.1m USD

Based on the financial report for Sep 30, 2024, Zymeworks Inc's Other Items amounts to 48.1m USD.

What is Zymeworks Inc's Other Items growth rate?
Other Items CAGR 5Y
5%

The average annual Other Items growth rates for Zymeworks Inc have been -38% over the past three years , 5% over the past five years .

Back to Top